Loading, please wait...
Date: Sep 8, 2023 03:00 AM - Dec 20, 2023 01:00 AM
Registration closes on Jan 01, 2024 12:00 AM
Title: Clear Your Plate: Antiplatelet Therapy for Stable Coronary Artery Disease in Anticoagulated Patients
Disclosure: Dr. Cox does not have any relevant financial relationship(s) with ineligible companies
Objectives:
Gap Analysis:
Atrial fibrillation and coronary disease are common comorbid conditions. Guidelines for Atrial fibrillation recommend an oral anticoagulant for all patients at risk of thrombosis based on their CHA2DS2-VASc score. Secondary prevention guidelines recommend lifelong aspirin for patients with coronary artery disease. Studies have shown significantly increased bleed risk when patients are on multiple antithrombotic agents. There is little data and no American guideline recommendations for what to do when a patient has stable CAD and is on anticoagulation for VTE or AFib. This presentation will examine the few studies, including the AFIRE trial, that have examined the safety/efficacy of an anticoagulant + antiplatelet vs anticoagulation alone in patients with stable coronary artery disease.
Title: Pharmacists’ Role in Addressing Social Determinants of Health
Objectives:
Disclosure: Dr. Robarts does not have any relevant financial relationship(s) with ineligible companies
Gap Analysis:
While there is increasing recognition of the impact of social determinants of health on overall health outcomes, pharmacists often focus primarily on medication management rather than the social and environmental factors that play a significant role in their patients’ lives. This gap is particularly evident in the limited training and education on SDOH, leaving pharmacists unequipped to effectively identify and address these factors. Furthermore, there is a lack of standardized protocols or guidelines for pharmacists to integrate SDOH into their practice. Additionally, the lack of consistent interprofessional collaboration between pharmacists and other healthcare team members further widens the gap, as a comprehensive approach to address SDOH requires a team-based effort. Closing these gaps requires a multi-pronged approach, including comprehensive training, standardized guidance, and enhanced collaboration between healthcare professionals. This presentation will examine available literature that exposes the significance of addressing SDOH, discuss the impact that the most accessible healthcare professionals - pharmacists - can have on these factors, and provide guidance on ways in which pharmacists can address SDOH in their daily practice.
Title: Protect Your Liquid Assets: An Update on Fluid Management in Sepsis
Faculty:
Diana Doan, PharmD
PGY-1 Resident
Dell Seton Medical Center at The University of Texas
Disclosure: Dr. Doan does not have any relevant financial relationship(s) with ineligible companies
Objectives:
Gap Analysis:
Literature continues to evolve related to ideal fluid management standards in sepsis and septic shock. The guidelines have been updated to address some of these new findings. This presentation helps to determine the "right" fluid and the "right" amount, exploring literature related to balanced vs. non-balanced crystalloids and liberal vs conservative fluid strategies.
The TOPCAT's out of the Bag: Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction
Learning Objectives:
Faculty:
Ma. Emmanuelle (Ella) Domingo, PharmD
PGY1 Pharmacy Resident
Dell Seton Medical Center at the University of Texas
Disclosure: Dr. Domingo does not have any relevant financial relationship(s) with ineligible companies
Gap Analysis: Heart failure is a disease state growing in prevalence with over 1.2 million heart failure hospitalizations in the United States. Guidelines for heart failure with preserved ejection fraction (HFpEF) have a class 2b recommendation for mineralocorticoid receptor antagonists (MRAs) to decrease heart failure hospitalizations in patients with left ventricular ejection fraction on the lower end of the spectrum. The definition of heart failure has evolved over time, particularly with various ranges of left ventricular ejection fraction in HFpEF literature. Studies have shown the potential benefit of MRAs for diastolic function. However, there is a paucity of strong data in regards to the benefit of MRAs in decreasing heart failure hospitalizations. This presentation will examine landmark trials in HFpEF, including the TOPCAT trial, that have examined the efficacy of MRAs in patients with HFpEF.
Title: What’s Your Type? Use of Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in the Treatment of Type 1 Diabetes (T1DM)
Faculty:
Samantha Tiano, PharmD, BCPS
PGY2 Ambulatory Care Pharmacy Resident CommUnityCare Health Centers
Disclosure: Dr. Tiano does not have any relevant financial relationship(s) with ineligible companies as defined by the ACPE Standards for Integrity and Independence.
Objectives:
Describe SGLT2i place in current practice
Analyze current evidence surrounding the use of SGLT2i for the treatment of T1DM
Identify strategies to reduce or minimize adverse effects with the use of SGLT2i in the setting of
T1DM
Apply current evidence of SGLT2i use for the treatment of T1DM to a patient case
Gap Analysis:
Diabetes has more than doubled over the last 20 years and is projected to triple by 2060. Pharmacologic advances are imperative to help control this growing epidemic. T1DM is about 5- 10% of all diabetes cases. The mainstay of treatment for T1DM remains insulin therapy even though 75% of cases fail to achieve glycemic goals and are burdened with unfavorable adverse effects, such as hypoglycemia and weight gain. Additional pharmacologic therapies are needed for the treatment of T1DM. There has been strong evidence for the use of SGLT2i in the setting of type 2 diabetes, chronic kidney disease, and heart-failure. Data and guideline recommendations regarding SGLT2i use for the treatment of T1DM are lacking. This presentation will examine available evidence, including meta-analyses of randomized controlled trials and real-world studies. A review of risk mitigation strategies with SGLT2i therapy will also be used to determine whether the benefits outweigh the risks with the use of SGLT2i in the setting of T1DM.